All Roll Calls
Yes: 380 • No: 33
Sponsored By: Representative Menendez, Robert [D-NJ-8]
Passed House
Creates an FCC advisory council focused on the security, reliability, and interoperability of U.S. communications networks. The bill would require the FCC Chair to set up or designate the council within 90 days, set membership rules, establish two-year terms, and require regular public reports.
Personalized for You
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
The FCC would need to set up or name a communications security council within 90 days. The Chair would appoint members for 2-year terms, and members could serve until a replacement takes office. Members would include industry, public-interest or academic groups, and federal, state, local, and Tribal officials, when practicable. The Chair could exclude entities the Chair publicly deems not trusted, such as those tied to a foreign adversary. Every 2 years, the council would send reports and recommendations to the Chair, and the FCC would post them online. The council would not automatically end under the usual advisory committee sunset rule.
Menendez, Robert [D-NJ-8]
NJ • D
Joyce (PA)
PA • R
Sponsored 4/1/2025
All Roll Calls
Yes: 380 • No: 33
house vote • 7/15/2025
On Motion to Suspend the Rules and Pass
Yes: 380 • No: 33
HR3151, SHIPS for America Act of 2025
Rebuild U.S. commercial shipbuilding and a U.S.-flag strategic fleet by pairing new tax credits, grants, and operating payments with stronger cargo-preference rules and workforce and innovation programs to restore domestic capacity and sealift readiness. It centralizes maritime strategy in a White House advisor and a Maritime Security Board and funds a broad set of industrial, port, and training programs to favor U.S.-built, U.S.-crewed vessels.
HR7977, Energy Bills Relief Act
Restores clean-energy tax credits. It also speeds permitting, expands low-income energy assistance and weatherization, and creates new transmission and resilience programs to move clean power faster and protect households. - Families and low-income households get broader help. LIHEAA eligibility rises to the greater of 250% of poverty or 80% of state median income and the bill sets a $2.0 billion baseline for FY2026 plus a $1.0 billion HEAP resilience grant program. - Grid operators, manufacturers, and utilities face new build-and-resilience rules. The bill funds a Strategic Transformer Resilience Program with a $2.1 billion Defense Production Act appropriation and adds a 6% transmission investment tax credit with wage and apprenticeship bonuses to speed domestic transmission buildout. - Offshore, territories, and workforce gains include territorial renewable grants, a Renewable Energy Resource Conservation Fund funded by lease revenues, required offshore project labor agreements, domestic-content rules phased to 2033, and capacity grants such as $25.0 million per year for community/offshore support programs.
HR4317, PBM Reform Act of 2025
Greater PBM transparency and tighter contract rules would require pharmacy benefit managers (PBMs) to disclose detailed per‑drug revenues and rebates, protect small "essential" retail pharmacies, and change Medicaid and group plan payment rules across the drug supply chain. The bill would layer reporting, audit rights, pass‑through pricing, and enforcement across Medicare Part D, ERISA/group plans, and Medicaid to spotlight hidden payments and affiliate flows. - Patients and community pharmacies: Would create an "essential retail pharmacy" label for pharmacies in underserved areas and require network access standards and biennial public data starting in 2028, helping small pharmacies show reimbursement and cost differences to plans. - PBMs, plans, and auditors: Would force PBMs to adopt flat bona fide service fees, disclose per‑drug claims, rebates, retained revenue, and affiliate dispensing shares, and give sponsors audit rights and remedies for improper remuneration. - States and Medicaid programs: Would require monthly national acquisition‑cost surveys, ban spread pricing in State Medicaid contracts, and mandate pass‑through pricing with itemized reporting and penalties for false data. Would increase federal spending for implementation by about $336 million in FY2025 and fund ongoing oversight including a $9 million annual IG appropriation.
HR6397, Dignity for Detained Immigrants Act
Creates comprehensive detention standards and independent oversight for people held by the Department of Homeland Security while phasing out private, for‑profit immigration detention and expanding community-based alternatives and legal protections. - Families and vulnerable people: Detention of vulnerable persons and primary caregivers is prohibited unless DHS shows community alternatives are unreasonable or impracticable. Unaccompanied children are exempt from this detention framework. - Detainees and due process: Initial custody decisions must occur within 48 hours and an immigration judge hearing must follow within 72 hours when custody is challenged. Proceedings carry a presumption of release, require least restrictive conditions, monthly reviews, a ban on solitary confinement, and mandatory legal orientation plus confidential access to counsel. - Facilities, oversight, and alternatives: The bill phases out private, for‑profit detention and requires DHS ownership or nonprofit operation within 3 years. It strengthens transparency with annual Office of Inspector General inspections, public monthly facility data, a detainee locator updated within 12 hours, and public reporting and root‑cause reviews of deaths in custody.
HR1262, Mikaela Naylon Give Kids a Chance Act
Speeds and strengthens pediatric cancer drug development. It expands which cancer products companies must study in children, reshapes organ transplant network governance and fees, and adds new FDA international and transparency steps. - Children with cancer and researchers: Requires pediatric studies that produce clinically meaningful data on dosing, safety, and early effectiveness and widens the kinds of drug combinations studied. It also sets aside $25 million for pediatric drug studies in each of fiscal years 2026, 2027, and 2028. - Transplant patients and transplant network members: Changes Organ Procurement and Transplantation Network governance and financing by allowing quarterly registration fees, requiring those fees fund OPTN operations, improving electronic health record integration, and calling for a GAO review within two years. - FDA partners and drug makers: Creates an Abraham Accords Office to boost regulatory coordination and technical assistance abroad, and forces more transparency during generic (ANDA) reviews about whether generics are qualitatively and quantitatively the same as listed drugs. It also raises the Medicare Improvement Fund amount from $1.4 billion to $2.6 billion. Increases federal outlays by roughly $1.3 billion, driven by a $1.2 billion boost to the Medicare Improvement Fund and $75 million for pediatric studies, adding to federal spending.
HR1227, Alternatives to PAIN Act
Lowering cost and access barriers for qualifying non-opioid pain management drugs under Medicare Part D. This bill would make certain non-opioid pain drugs cheaper and easier to get for Medicare enrollees. - Medicare Part D enrollees would pay less out of pocket because qualifying non-opioid pain drugs would not be subject to the Part D deductible and must be placed on the lowest cost-sharing tier when calculating maximum co-insurance or other cost-sharing. These changes apply for plan years beginning on or after January 1, 2026. - Low-income Medicare enrollees who receive Part D subsidies would get the same deductible waiver and lowest-tier placement for qualifying drugs when calculating their maximum cost-sharing, for plan years beginning on or after January 1, 2026. - Prescription drug plans and Medicare Advantage prescription drug plans would be barred from imposing step therapy or prior authorization for qualifying non-opioid pain drugs, reducing administrative hurdles for patients and providers beginning in 2026. - A qualifying non-opioid pain drug must have an FDA-approved indication for acute or postoperative pain, not act on opioid receptors, lack a therapeutically equivalent U.S. product, and have a monthly wholesale acquisition cost below a specialty-tier cost threshold that the Secretary may set and update.
Surfaced from PRIA's policy knowledge graph, ranked by signal strength, connected by evidence.
The Lacey Act 16 U.S.C. §§ 3371–3378 is America's oldest and broadest wildlife protection law — and since a 2008 amendment, it also covers plants and plant products including timber. Originally enacte
The federal government distributes more than $800 billion per year in grants — more money than the entire U.S. defense discretionary budget — yet most Americans have no mental model of how grant fundi
The U.S. federal government spent approximately $6.75 trillion in FY 2024, making it the world's largest economy in its own right — but most of that money never touches the Treasury in the way most pe
Every AM radio station, FM station, television broadcaster, and noncommercial educational broadcaster in the United States operates under a federal license governed by 47 CFR Part 73 — the FCC's compr